New tool helps decide what drugs to include in health care formularies

A new tool that could provide a useful framework for deciding what medicines to include in drug formularies is presented in this week's PLoS Medicine by the experts from Harvard Medical School and the University of Illinois at Chicago who developed it.

The experts, led by Gordon Schiff, say: "Formularies and committees that oversee them are present in some form in virtually every US hospital and outpatient drug plan and are highly visible components of public benefits in many countries. Thus decisions made by these committees directly or indirectly impact every prescriber, , and patient."

Although considerable attention has been devoted to their role in cost containment, the authors argue that "formularies' role in guiding rational remains underdeveloped and could be improved by a more standardized critical evaluation of drugs proposed for formulary placement."

So in a joint project, the authors developed a tool consisting of checklist of 48 questions for evaluating drugs to be considered for inclusion in the formulary related to the evidence of need, efficacy, , misuse potential, cost issues, and decision-making process.

The authors say: "The checklist can facilitate more standardized and critical scrutiny of the evidence and therapeutic alternatives. It can educate new committee members, guide discussions of drugs proposed for formulary addition, and be used to evaluate the quality of committee decision making."

The authors conclude: "we offer the tool for a broader audience to use and test. We hope that it will prove useful in improving the quality of formulary decision making and stimulating debate related to critical questions that need to be asked, highlighting essential data needed to more safely prescribe drugs."

More information: Schiff GD, Galanter WL, Duhig J, Koronkowski MJ, Lodolce AE, et al. (2012) A Prescription for Improving Drug Formulary Decision Making. PLoS Med 9(5): e1001220. doi:10.1371/journal.pmed.1001220

add to favorites email to friend print save as pdf

Related Stories

Higher co-payments reduce use of antidepressants

Jun 07, 2008

As they struggle to contain skyrocketing medication costs, health plans across the U.S. have responded by implementing multi-tiered formularies requiring higher copayments for 'non-preferred' medications. New research from ...

US Medicaid drug lists cost more, deliver less

Jun 17, 2011

The U.S. Medicaid program is likely paying far more than necessary for medications and not offering patients the most effective ones available, by ignoring international evidence-based lists of safe and effective medications, ...

Recommended for you

Supermaterial gives rejected drugs a new chance

14 hours ago

More than 80 percent of all drug candidates in the pharma R&D suffer from poor solubility and are therefore rejected early in the drug discovery process. Now Uppsala University researchers show that the new ...

Risk of antibiotic overuse in aged care settings

Jul 21, 2014

Antibiotics are being overused in residential aged care facilities (RACFs), and more integrated efforts to improve antibiotic prescribing practices need to be introduced, researchers say. 

Ruconest approved for rare genetic disease

Jul 17, 2014

(HealthDay)—Ruconest has been approved by the U.S. Food and Drug Administration to treat hereditary angioedema, a genetic disease that leads to sudden and potentially fatal swelling of the hands, feet, limbs, face, intestinal ...

NIH system to monitor emerging drug trends

Jul 17, 2014

An innovative National Drug Early Warning System (NDEWS) is being developed to monitor emerging trends that will help health experts respond quickly to potential outbreaks of illicit drugs such as heroin and to identify increased ...

User comments